Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 31, 2007PLoS MedicineOpen Access

Building Clinical Trials Capacity for Tuberculosis Drugs in High-Burden Countries

View Full Paper
Ask AI
Bookmark
Share

Authors

NSNeil W. SchlugerNew York Medical CollegeUKUnni KarunakaraYale New Haven Health SystemCLChristian LienhardtInserm

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Schluger et al. (2007) studied this question.

synapsesocial.com/papers/6a9653b4f69cd3f69201f8f9https://doi.org/10.1371/journal.pmed.0040302
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine Tuberculosis2004 · 221 citations
  2. 2Acquired Rifamycin Resistance with Twice-Weekly Treatment of HIV-related Tuberculosis2005 · 155 citations
  3. 3Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis2006 · 288 citations
  4. 4Potent Twice-Weekly Rifapentine-containing Regimens in Murine Tuberculosis2006 · 90 citations